# Gene Therapy for Chronic Granulomatous Disease in Korea

> **NCT00778882** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Helixmith Co., Ltd.**

## Conditions studied

- Chronic Granulomatous Disease

## Interventions

- **DRUG:** VM106

## Key facts

- **NCT ID:** NCT00778882
- **Lead sponsor:** Helixmith Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-01
- **Primary completion:** 2008-10
- **Final completion:** 2010-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This Korean Phase 1 study was Withdrawn more than 15 years ago and no data is available.
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00778882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00778882, "Gene Therapy for Chronic Granulomatous Disease in Korea". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00778882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*